Treace Medical Concepts (TMCI) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew to $45.1 million, up 11% year-over-year, driven by adoption of new technologies and increased surgeon activity.

• Net loss for Q3 2024 was $15.4 million ($0.25 per share), improved from $17.5 million ($0.28 per share) in Q3 2023.

• Launched Nanoplasty 3D MIS system, entering the large metatarsal osteotomy market and expanding the product portfolio.

• Expanded patent portfolio and filed a patent infringement and unfair competition lawsuit against Stryker Corporation and Wright Medical.

• Cash, cash equivalents, and marketable securities totaled $82.8 million as of September 30, 2024.

Financial highlights

• Q3 2024 revenue reached $45.1 million, up 11% year-over-year; gross margin was 80.1%, nearly flat from 80.4% in Q3 2023.

• Gross profit for Q3 2024 was $36.1 million.

• Operating expenses increased to $51.3 million in Q3 2024, reflecting higher R&D and share-based compensation.

• Adjusted EBITDA loss was $5.1 million, a 45% improvement year-over-year and 42% sequentially.

• Net loss per share improved to $(0.25) from $(0.28) year-over-year.

Outlook and guidance

• Full year 2024 revenue guidance revised to $204–$211 million, representing 9%–13% growth over 2023.

• Adjusted EBITDA improvement of approximately 50% expected for full year 2024 versus 2023.

• Targeting Adjusted EBITDA break-even in 2025, with most improvement expected in the fourth quarter.

• Management expects macroeconomic challenges, including inflation and competition, to continue impacting results.

• Existing cash, marketable securities, available debt, and expected revenues are believed sufficient to fund operations for at least 12 months.